NCT06946927

A Phase Ib Study of JMKX001899 in Combination With Other Therapies in Advanced NSCLC Harboring KRAS G12C Mutation

A Phase Ib, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of JMKX001899 in Combination With Other Therapies in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With KRAS G12C Mutation.

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 72 (estimated)
• Sponsor: Jemincare · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is a phase 1b, dose escalation and expansion study to evaluate the safety, tolerability, pharmacokinetics and efficacy of JMKX001899 in combination with IN10018 or in combination with chemotherapy or in combination with IN10018 and chemotherapy in subjects with locally advanced or metastatic NSCLC with KRAS G12C mutation.

Conditions

• NSCLC (Advanced Non-small Cell Lung Cancer)

Interventions

Type	Name	Description
DRUG	JMKX001899	JMKX001899 tablet administered orally daily.
DRUG	IN10018	IN10018 tablet administered orally daily.
DRUG	Chemotherapy: Pemetrexed	IV infusion once every 3 weeks
DRUG	Carboplatin	IV infusion once every 3 weeks, 4 Cycles

Timeline

• Start date: 2025-06-06
• Primary completion: 2026-02-01
• Completion: 2027-12-01
• First posted: 2025-04-27
• Last updated: 2025-07-01

Locations

1 site across 1 country: China